• Recruiting

NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma

Updated: Sep 16

NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma


Newly Diagnosed Multiple Myeloma

Relapsed Refractory Multiple Myeloma

teclistamab MAJESTEC STUDY

The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.


Sponsor

Janssen Research & Development, LLC


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT04722146

Official Title: A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

First Posted : January 25, 2021

Click here for details on ClinicalTrials.gov


A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma | Global Trial Finder (janssen.com)

 

JNJ 64007957 - Tteclistamab

Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody JNJ-64007957

JNJ 64007957

JNJ-64007957

JNJ64007957

Teclistamab


Nirogacestat

 

* Bortezomib (Velcade)

* Lenalidomide (Revlimid)

* Pomalidomide(Pomalyst)

* Daratumumab (Darzalex)

 

- Alabama: University of Alabama at Birmingham

- California: University of California San Francisco

- Georgia: Emory University Atlanta

- Indiana: Indiana University Indianapolis

- Missouri: Washington University School of Medicine Saint Louis

- New York: Memorial Sloan-Kettering Cancer Center New York

- New York: Tisch Cancer Institute Mount Sinai Hospital New York

- New York: New York Presbyterian / Weill Cornell Medical College New York

- New Jersey: Hackensack University Medical Center

- North Carolina: Levine Cancer Institute Charlotte

- Pennsylvania: University of Pittsburgh Medical Center

- Tennessee: Sarah Cannon Research Institute Nashville

- Washington: Seattle Cancer Care Alliance

- Wisconsin: Medical College Of Wisconsin Milwaukee

 

Locations

United States, Alabama

United States, California

United States, Colorado

United States, Georgia

United States, Indiana

United States, Kansas

United States, Missouri

United States, New Jersey

United States, New York

United States, North Carolina

United States, Pennsylvania

United States, Tennessee

United States, Washington

United States, Wisconsin


Europe

United Kingdom

France

Belgium


Australia

 

RELATED POSTS


TECLISTAMAB STUDIES:


NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma (MajesTEC1)

Click here for details


NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)

Click here for details


NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - (MajesTEC-3)

Click here for details


NCT05243797: Phase 3: Tec + Len Vs Len Alone in NDMM as Maintenance Therapy Post ASCT (MajesTEC-4)

Click here for details


NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)

Click here for details

 

TALQUETAMAB STUDIES:


NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1

Click here for details


NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma

Click here for details


NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma

Click here for details


NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma

Click here for details

 

TECLISTAMAB AND TALQUETAMAB STUDIES:


NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma

Click here for details


NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2

Click here for details








Posts Archive